Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.
Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and in the treatment of narcolepsy (a Special type of sleep disorder), Zydus Cadila said.
The drug will be sold in extended-release capsules of 5 mg dosage.
It will be produced at the Nesher Pharmaceuticals manufacturing facility located at St. Louis, Missouri, USA.
Zydus Cadila employs over 20,000 people worldwide and is one of the world’s largest generic drug manufacturers.
The company “aspires to be a research-based pharmaceutical company” by 2020.